HD Merrimack Company Profile

19:26 EST 23rd November 2017 | BioPortfolio

News Articles [24 Associated News Articles listed on BioPortfolio]

Technical Snapshots for These Biotech Stocks -- Merrimack Pharma, MannKind, GlycoMimetics, and ... Merrimack Pharma  Shares in Cambridge, Massachusettsheadquartered Merrimack Pharmaceuticals Inc. saw a drop of 2.31%, ending Tuesday's trading session at $1...

Merrimack appoints Thomas Needham chief business officer

Merrimack Pharmaceuticals announced further expansion of its executive management team with the appointment of Thomas E. Needham, Jr., M.B.A., to the position of chief business officer. In this role...

Merrimack Commences Tender Offer For Any And All Of Its Outstanding 4.50% Convertible Senior Notes Due 2020

CAMBRIDGE, Mass., Oct. 13, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (NASDAQ: MACK) (the "Company" or "Merrimack") today announced that it has commenced a tender offer (the "Tender Offer") to pur...

FDA orphan status given to Merrimack's heregulin-positive lung cancer drug

Merrimack Pharmaceuticals' MM-121, or seribantumab, which is being developed to treat patients with heregulin-positive non-sm -More- 

Merrimack Reports Third Quarter 2017 Financial Results

"The third quarter marked continued execution on our 2017 goals as we delivered on the promise of a refocused Merrimack with a seasoned team built Read more...

Merrimack Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 15062017] Prices from USD $350

Merrimack Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Merrimack Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alli...

Merrimack: A Special Situation With A Compelling Risk/Reward

Management tracks: Cerecor, Allakos, Epizyme, Merrimack

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis

Merrimack is conducting a research study to see if an experimental drug, called MM-093, is safe and effective in the treatment of psoriasis. MM-093 is a genetically engineered version of a...

Companies [8 Associated Companies listed on BioPortfolio]

Merrimack Pharmaceuticals, Inc.

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a ro...

Merrimack Pharmaceuticals,Inc.

Merrimack Pharmaceuticals, Inc. is a privately held biotechnology company based in Cambridge, Massachusetts. We are dedicated to the discovery and development of innovative therapies for the treatmen...

HD Merrimack

PharmaEngine Inc.

PharmaEngine, Inc. is a biopharmaceutical company established in Taipei, Taiwan in 2003. PharmaEngine focuses on the development of new treatments for cancer and Asian prevalent d...

Eleme Medical Inc.

Eleme Medical Inc., headquartered in Merrimack, N.H., is dedicated to providing market-leading technology in all areas of body shaping. SmoothShapes® system with pioneering Photomology® technology i...

More Information about "HD Merrimack" on BioPortfolio

We have published hundreds of HD Merrimack news stories on BioPortfolio along with dozens of HD Merrimack Clinical Trials and PubMed Articles about HD Merrimack for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of HD Merrimack Companies in our database. You can also find out about relevant HD Merrimack Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record